Myobloc, Neurobloc(rimabotulinumtoxinb)
Myobloc (rimabotulinumtoxinb) is an unknown pharmaceutical. Rimabotulinumtoxinb was first approved as Myobloc on 2000-12-08. It is used to treat dystonia and neck pain in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Myobloc
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Rimabotulinumtoxinb
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Myobloc | rimabotulinumtoxinB | Solstice NeuroSciences | N-103846 RX | 2000-12-08 | 3 products |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
rimabotulinumtoxinb, Myobloc, Solstice NeuroSciences, LLC | |||
| 2107-12-08 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0587 | Injection, rimabotulinumtoxinb, 100 units |
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasticity | D009128 | — | — | — | 2 | 2 | 1 | — | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | 1 | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 1 | 1 | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | 1 | 1 | — | 2 |
| Brain injuries | D001930 | — | S06.9 | — | 1 | 1 | 1 | — | 2 |
| Dystonic disorders | D020821 | — | G24 | — | — | — | 2 | — | 2 |
| Dystonia | D004421 | — | — | — | — | — | 2 | — | 2 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | — | 1 |
| Muscular atrophy | D009133 | — | — | — | — | — | 1 | — | 1 |
| Torticollis | D014103 | — | F45.8 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | 1 | — | — | 1 |
| Cerebral palsy | D002547 | — | G80 | — | 1 | 1 | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Sialorrhea | D012798 | — | K11.7 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rimabotulinumtoxinb |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
|
| Classification | Neurotoxin |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108710 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Daxxify – Revance Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Myobloc – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,183 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daxxify, Dysport, Myobloc
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
339 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use